CEO and Chief Medical Officer
COLUMBIA ASIA HOSPITALS
United States Virgin Islands
David Portman MD, Sermonix CEO and Chief Medical Officer, was a principal investigator for the Phase II and III lasofoxifene trials and a consultant during its drug development. Dr. Portman has experience in all stages of the regulatory approval process and has worked with the FDA on numerous types of pre-approval and approval meetings, advisory committees, and submission and approval considerations. He has worked with the medical, marketing, launch and sales aspects of many products in the women’s healthcare space.
Phase II and III lasofoxifene trials and a consultant